Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Tobler

Showing results (141-150 of 151) with videos related to

Pageof 16
Sort By:
Cell Death and Differentiation|December 26, 2001
Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53T J Grob, U Novak, C Maisse, et al.
Biochemical and Biophysical Research Communications|October 12, 2000
Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemiaM P Tschan, T J Grob, U R Peters, et al.
Leukemia|October 17, 2003
Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trialG Buesche, R Hehlmann, H Hecker, et al.
Leukemia|February 3, 2006
Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemiaO Maywald, M Pfirrmann, U Berger, et al.
Leukemia|April 1, 1997
Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study GroupR Hehlmann, A Willer, H Heimpel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001
Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemiaU Novak, T J Grob, G Baskaynak, et al.
Leukemia|July 31, 2004
Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemiaG Buesche, M Freund, R Hehlmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2002
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II studyA von Rohr, S-F H Schmitz, A Tichelli, et al.
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Bone Marrow Transplantation|May 1, 1996
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study GroupR Hehlmann, H Heimpel, D K Hossfeld, et al.
Pageof 16

Showing results (141-150 of 151) with videos related to

Sort By:
Pageof 16
Cell Death and Differentiation|December 26, 2001
Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53T J Grob, U Novak, C Maisse, et al.
Biochemical and Biophysical Research Communications|October 12, 2000
Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemiaM P Tschan, T J Grob, U R Peters, et al.
Leukemia|October 17, 2003
Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trialG Buesche, R Hehlmann, H Hecker, et al.
Leukemia|February 3, 2006
Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemiaO Maywald, M Pfirrmann, U Berger, et al.
Leukemia|April 1, 1997
Randomized studies with interferon in chronic myelogenous leukemia (CML) and comparative molecular aspects. German CML Study GroupR Hehlmann, A Willer, H Heimpel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001
Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemiaU Novak, T J Grob, G Baskaynak, et al.
Leukemia|July 31, 2004
Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemiaG Buesche, M Freund, R Hehlmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2002
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II studyA von Rohr, S-F H Schmitz, A Tichelli, et al.
Blood|November 26, 1999
Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedureR Hehlmann, A Hochhaus, H J Kolb, et al.
Bone Marrow Transplantation|May 1, 1996
Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study GroupR Hehlmann, H Heimpel, D K Hossfeld, et al.
Pageof 16